Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Pralsetinib | Altai Oncology - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Indication: Pralsetinib for advanced RET-mutated thyroid cancer

New Indication: Pralsetinib for advanced RET-mutated thyroid cancer
  • Phase I/II, single arm (ARROW trial)
  • Advanced RET mutation-positive RAI-refractory thyroid cancer (n=9, all had papillary thyroid cancer)
  • ORR: 89% (52% – 100%), all PR
  • Duration of response over 6 months all patients
  • Grade 3-4 AEs: Neutropenia (16%), hypertension (14%), hypophosphatemia (11%), pneumonia (8%), interstitial lung disease (3%)

Not published yet (Nov 2020)


Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More